---

Medical Advocates Ethics and Infectious Diseases
		Ethical Challenges Screening/Testing Refusal of Care/Services Detention Patient Exploitation Compulsory Treatment Decision-Making Reproduction Transplants End-of-Life Care Enteral Nutrition Professional Associations National Challenges         Sterilization Bioterrorism                     Prison Challenges HIV Exceptionalism           Conflicts of Interest Pharmaceutical Industry   Pregnancy HIV Prevention    Stigma Physician Reimbursement  Ethics and Disease Challenges and Duties HIV Cure Ebola Virus Disease Executions

---

Ethics Main Page

Main New and Noteworthy

Home Page

---

Medical Advocates Darunavir(Prezista/TMC-114)

Conference Archives – B 17th Annual Canadian Conf on HIV/AIDS Research 14th CROI IDSA – 2006 HEP DART 2006 46th ICAAC Conference Archives- C

---

Conferences Main Page

Main New and Noteworthy

Home Page

---

Last Update:  December 04, 2008   Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader Pediatric data are indexed in the pediatric section   The 17th Annual Canadian Conference on HIV/AIDS Research (CAHR 2007) POSTER Accuracy and Correlation of Response Predictions based on 4 Methodologies to Interpret Darunavir Resistance in patients receiving Darunavir Containing Regimens in the POWER Studies J Villacian, B Winters, K Van der Borght, et al PDF Poster

---

14th CROI

---

POSTER Phenotypic Susceptibility in vitro to Amprenavir, Atazanavir, Darunavir, Lopinavir, and Tipranavir of HIV-2 Clinical Isolates from the French ANRS HIV-2 Cohort D Desbois, G Peytavin, S Matheron, et al PDF Poster POSTER In-vitro Selection of HIV-1 Variants Highly Resistant to Darunavir (DRV) Using a Mixture of HIV-1 Isolates Resistant to Multiple Protease Inhibitors (PIs) Y Koh, T Towata, AK Goshi, et al PDF Poster POSTER Binding Kinetics of PI to Wild Type and Multi-drug Resistant HIV-1 Proteases: A Mechanistic Study of the Genetic Barrier to Resistance of Darunavir M De Wit, I Keuleers, E Gustin, et al PDF Poster Defining the Upper and Lower Phenotypic Clinical Cut-offs for Darunavir/Ritonavir by the PhenoSense Assay E Coakley, C Chappey, J Benhamid, et al Abstract Prior Utilization or Resistance to Amprenavir at Screening Has Minimal Effect on the 48-Week Response to Darunavir/r in the POWER 1, 2, and 3 Studies G Picchio, T Vangeneugden, B Van Baelen, et al Abstract Darunavir/Amprenavir Cross-resistance in Clinical Samples Submitted for Phenotype/Genotype Combination Resistance Testing N Parkin, E Stawiski, C Chappey,  E Coakley Abstract POSTER TMC114/r tolerability in treatment-experienced, hepatitis B or C (HBV/HCV) co-infected patients in POWER 1 and 3 Rachlis A, Clotet B, Baxter J, et al PDF Poster POSTER Pharmacokinetic interaction between the antiretroviral agents TMC114 and nevirapine, in the presence of low-dose ritonavir Sekar V, Lefebvre E, Mariën K, et al PDF Poster POSTER Pharmacokinetic interaction between the HIV protease inhibitors TMC114 and saquinavir, in the presence of low-dose ritonavir Sekar V, Lefebvre E, Mariën K , et al PDF Poster

---

HEP DART 2006

---

• POSTER
  Prevalence of darunavir-associated mutations in samples received for routine clinical resistance testing
  AR Rinehart, G Picchio; M-P de Bethune, et al
  PDF Poster
• POSTER
  Single-center experience of darunavir (DRV) in 38 HIV-infected adults enrolled in US expanded
  access program
  J Gathe, Jr, K Degazon, ; C Mayberry, et al
  PDF Poster
• POSTER
  Examination of factors influencing response to darunavir combined with low-dose ritonavir
  in POWER 1, 2, and 3: Pooled 48-week analysis
  J Gathe,  E deJesus, R Falcon, et al
  PDF Poster
• POSTER
  Safety and efficacy of darunavir in combination with low-dose ritonavir
  P Ruane, JE Gallant, A Tennenberg, SS Guzman
  PDF Poster

---

46th ICAAC

POSTER Impact of use of TPV, LPV and (f)APV at screening on TMC114/r virologic response in treatment-experienced patients in POWER 1, 2 and 3 Lefebvre E, de Béthune M-P, De Meyer S, et al PDF Poster POSTER Body mass change and anthropometric-related adverse events at Week 24 in treatment experienced HIV-infected patients receiving TMC114/r or control PIs in POWER 1, 2 and 3 Roberts A, Hoy J, Beatty G, et al PDF Poster POSTER Pharmacokinetic interaction between the protease inhibitors TMC114 and lopinavir/ritonavir Sekar V, Lefebvre E, Spinosa-Guzman S, et al PDF Poster POSTER Pharmacokinetic interaction between ethinyl estradiol, norethindrone and TMC114, a new protease inhibitor Sekar V, Lefebvre E, Spinosa-Guzman S, et al PDF Poster